Twist Bioscience Corporation $TWST Shares Newly Purchased by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 28,895 shares of the company’s stock, valued at approximately $5,584,000. Twist Bioscience comprises about 1.5% of Lisanti Capital Growth LLC’s holdings, making the stock its 20th largest holding.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in shares of Twist Bioscience in the 2nd quarter worth approximately $600,191,000. William Blair Investment Management LLC purchased a new stake in Twist Bioscience during the 2nd quarter worth about $223,722,000. Bank of America Corp DE purchased a new stake in shares of Twist Bioscience during the second quarter worth approximately $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of Twist Bioscience in the 1st quarter valued at $22,563,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Twist Bioscience during the 2nd quarter worth about $19,722,000.

Twist Bioscience Stock Down 7.2%

NASDAQ:TWST opened at $122.59 on Thursday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The company has a market capitalization of $7.69 billion, a price-to-earnings ratio of -55.22 and a beta of 2.25. Twist Bioscience Corporation has a one year low of $23.30 and a one year high of $219.71. The stock has a 50-day simple moving average of $150.90 and a 200 day simple moving average of $92.37.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Robert W. Baird raised their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Jefferies Financial Group assumed coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 price objective for the company. Piper Sandler lifted their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 5th. Leerink Partners raised their price target on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Finally, Guggenheim raised their target price on shares of Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $153.00.

Insider Activity at Twist Bioscience

In related news, CAO Robert F. Werner sold 1,482 shares of the business’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $279,920.16. Following the completion of the transaction, the chief accounting officer owned 42,917 shares in the company, valued at $8,106,162.96. The trade was a 3.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 949 shares of the stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $135.40, for a total transaction of $128,494.60. Following the completion of the sale, the insider directly owned 62,840 shares in the company, valued at approximately $8,508,536. This trade represents a 1.49% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 495,279 shares of company stock valued at $80,489,387 in the last ninety days. 3.08% of the stock is owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.